HRP20192174T1 - Kombinirani farmaceutski pripravak - Google Patents
Kombinirani farmaceutski pripravak Download PDFInfo
- Publication number
- HRP20192174T1 HRP20192174T1 HRP20192174TT HRP20192174T HRP20192174T1 HR P20192174 T1 HRP20192174 T1 HR P20192174T1 HR P20192174T T HRP20192174T T HR P20192174TT HR P20192174 T HRP20192174 T HR P20192174T HR P20192174 T1 HRP20192174 T1 HR P20192174T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- antibody
- seq
- amino acid
- acid sequence
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 230000027455 binding Effects 0.000 claims 8
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims 7
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 7
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 7
- 102000056003 human IL15 Human genes 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000003812 Interleukin-15 Human genes 0.000 claims 5
- 108090000172 Interleukin-15 Proteins 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 101001003140 Homo sapiens Interleukin-15 receptor subunit alpha Proteins 0.000 claims 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000008088 immune pathway Effects 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 230000007896 negative regulation of T cell activation Effects 0.000 claims 3
- 229940123751 PD-L1 antagonist Drugs 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 229940124060 PD-1 antagonist Drugs 0.000 claims 1
- 229940121678 PD-L2 antagonist Drugs 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Claims (12)
1. Kombinirani farmaceutski pripravak koji sadrži:
a) konjugat koji sadrži
(i) polipeptid koji sadrži aminokiselinsku sekvencu interleukina 15 ili njegovih derivata koji imaju najmanje 10% aktivnosti ljudskog IL-15 na indukciju proliferacije stanice kit225, i
(ii) polipeptid koji sadrži aminokiselinski slijed suši domene IL-15Rα ili njegovih derivata koji imaju najmanje 10% aktivnosti vezanja suši domene ljudskog IL-15Rα na humani IL-15, polinukleotid koji kodira, ili vektor koji sadrži takav polinukleotid; i
b) antitijelo koje antagonizira imunološki put uključeno u inhibiciju aktivacije T stanice, ili njegov fragment koji može reagirati s istim antigenom kao njegovo odgovarajuće antitijelo, polinukleotid koji kodira, ili vektor koji sadrži takav polinukleotid, pri čemu je spomenuto antitijelo antagonist PD-1/PD-L1/PD-L2, pri čemu se spomenuto antitijelo antagonizira bilo vezanjem PD-1 receptora ili vezanjem PD-L1 ili PD-L2 liganda; pri čemu navedeni konjugat i njegovo antitijelo ili fragment nisu povezani.
2. Farmaceutski pripravak za uporabu u liječenju raka kod subjekta koji sadrži
(A) konjugat koji sadrži
(i) polipeptid koji sadrži aminokiselinsku sekvencu interleukina 15 ili njegovih derivata koji imaju najmanje 10% aktivnosti ljudskog IL-15 na indukciju proliferacije stanice kit225, i
(ii) polipeptid koji sadrži aminokiselinski slijed suši domene IL-15Rα ili njegovih derivata koja ima najmanje 10% aktivnosti vezivanja suši domene ljudskog IL-15Rα na humani IL-15, polinukleotid koji kodira, ili vektor koji sadrži takav polinukleotid, pri čemu se uporaba sastoji istovremeno, odvojeno ili uzastopno davanje
(a) navedenog lijeka pripravka i
(b) antitijelo koje antagonizira imunološki put uključeno u inhibiciju aktiviranja T stanica, ili njegov fragment koji može reagirati s istim antigenom nego njegovo odgovarajuće antitijelo, polinukleotidno kodiranje prema tome, ili vektor koji sadrži takav polinukleotid, ili
(B) antitijelo koje antagonizira imunološki put uključeno u inhibiciju aktivacije T stanice, ili njegov fragment koji je sposoban reagirati s istim antigenom kao njegov kolega s antitijelom, polinukleotid koji kodira, ili vektor koji sadrži takav polinukleotid, pri čemu se upotreba sastoji istovremeno, odvojeno ili uzastopno davanje
(a) navedenog farmaceutskog pripravka i
(b) konjugat koji sadrži
(i) polipeptid koji sadrži aminokiselinski slijed interleukina 15 ili njihovi derivati koji imaju najmanje 10% aktivnosti ljudskog IL-15 na indukciju proliferacije kit225 stanična linija i
(ii) polipeptid koji sadrži aminokiselinski slijed suši domene IL-15Rα ili njihovi derivati koji imaju najmanje 10% aktivnosti vezivanja suši domene ljudskog IL-15Rα na humani IL-15, polinukleotid koji kodira, ili vektor koji sadrži takav polinukleotid, i pri čemu je navedeno protutijelo antagonist PD-1/PD-L1/PD-L2, pri čemu se navedeno antitijelo antagonizira bilo vezanjem PD-1 receptora ili vezanjem PD-L1 ili PD-L2 liganda.
3. Farmaceutski pripravak za uporabu u liječenju raka prema zahtjevu 2 ili kombinirani farmaceutski pripravak prema zahtjevu 1, prilagođen za istovremeno, odvojeno ili sekvencijalno davanje za uporabu u liječenju raka kod subjekta.
4. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 3, naznačen time, da:
a) konjugat se daje injekcijom u dozi od 60 µg/kg ili manje, poželjno u dozi od 10 µg/kg ili manje, a najpoželjnije u dozi od 5 µg/kg ili manje; i
b) antitijelo koje antagonizira imunološki put je uključeno u inhibiciju aktivacije T stanica, ili se njegov fragment daje injekcijom u dozi od 500 µg/kg ili manje, poželjno u dozi od 100 µg/kg ili manje, a najpoželjnije u dozi od 50 µg/kg ili manje.
5. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 4, naznačen time, da je spomenuto antitijelo antagonist PD-1/PD-L1.
6. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 5, naznačen time, da navedeni derivat interleukina 15 ima najmanje 25% aktivnosti humanog interleukina-15 na indukciju proliferacije stanične linije kit225, poželjnije najmanje 50%, ili ima aminokiselinsku sekvencu koja ima postotak identiteta od najmanje 92,5% s aminokiselinskom sekvencom odabranom u grupi koja se sastoji od SEQ ID n°: 1, SEQ ID n°: 2 i SEQ ID nº: 3, po mogućnosti od najmanje 96% i poželjnije najmanje 98,5% ili najmanje 99%.
7. Farmaceutski pripravak ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 6, naznačen time, da navedeni derivat suši domene IL-15Rα ima najmanje 25%, poželjnije najmanje 50% vezivne aktivnosti suši domene ljudskog IL-15Rα, ili ima aminokiselinsku sekvencu koja ima postotak identičnosti od najmanje 92% sa aminokiselinskom sekvencom odabranom u grupi koja se sastoji od SEQ ID n°: 4, SEQ ID n°: 5, SEQ ID n°: 6, SEQ ID n°: 7, SEQ ID n°: 8 i SEQ ID n°: 9, poželjno najmanje 96%, a poželjnije najmanje 98%.
8. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 7, naznačen time, da je spomenuto antitijelo izabrano između antagonista PD-1 / PD-L1 i PD-1 / PD-L2, poželjno nivolumaba, Merck 3745, CT-01 1, lambrolizumaba, AMP514, MDX-1 105 ili YW243.55.S70.
9. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 8, naznačen time što su polipeptidi (i) i (ii) konjugata kovalentno povezani u fuzijskom proteinu.
10. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 9, naznačen time, da navedeni interleukin 15 ima aminokiselinsku sekvencu SEQ ID n°: 1.
11. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 10, naznačen time što suši domena IL-15Rα ima aminokiselinsku sekvencu SEQ ID n°: 4.
12. Farmaceutski pripravak za uporabu u liječenju raka ili kombinirani farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 11, naznačen time da konjugat ima sekvencu SEQ ID n°: 16 ili SEQ ID n°: 17.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003964 | 2013-08-08 | ||
| PCT/EP2014/002182 WO2015018529A1 (en) | 2013-08-08 | 2014-08-08 | Combined pharmaceutical composition |
| EP14761281.6A EP3030262B1 (en) | 2013-08-08 | 2014-08-08 | Combined pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192174T1 true HRP20192174T1 (hr) | 2020-03-06 |
Family
ID=48951300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192174TT HRP20192174T1 (hr) | 2013-08-08 | 2019-12-02 | Kombinirani farmaceutski pripravak |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20160184399A1 (hr) |
| EP (2) | EP3659622A1 (hr) |
| JP (3) | JP6794255B2 (hr) |
| KR (2) | KR102457731B1 (hr) |
| CN (1) | CN105579062A (hr) |
| CA (1) | CA2920539C (hr) |
| CY (1) | CY1122465T1 (hr) |
| DK (1) | DK3030262T3 (hr) |
| ES (1) | ES2760249T3 (hr) |
| HR (1) | HRP20192174T1 (hr) |
| HU (1) | HUE046964T2 (hr) |
| LT (1) | LT3030262T (hr) |
| PL (1) | PL3030262T3 (hr) |
| PT (1) | PT3030262T (hr) |
| RS (1) | RS59756B1 (hr) |
| SI (1) | SI3030262T1 (hr) |
| WO (1) | WO2015018529A1 (hr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2251034T3 (pl) | 2005-12-02 | 2018-07-31 | Icahn School Of Medicine At Mount Sinai | Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów |
| BR112015021414B1 (pt) | 2013-03-14 | 2020-11-10 | Icahn School Of Medicine At Mount Sinai | vírus da doença newcastle e seus usos |
| KR102457731B1 (ko) * | 2013-08-08 | 2022-10-21 | 싸이튠 파마 | 병용 약학 조성물 |
| SG11201607130RA (en) | 2014-02-27 | 2016-09-29 | Viralytics Ltd | Combination method for treatment of cancer |
| EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| CN115058395A (zh) | 2015-06-25 | 2022-09-16 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| WO2017046200A1 (en) * | 2015-09-16 | 2017-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| EP3402508A4 (en) * | 2016-01-11 | 2019-09-25 | Flagship Pioneering Innovations V, Inc. | METHOD AND COMPOSITIONS FOR MODULATING THE THYMUS FUNCTION |
| EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| CA3024509A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| AU2017283480A1 (en) | 2016-06-13 | 2019-01-24 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| US20200283534A1 (en) * | 2016-06-24 | 2020-09-10 | iCell Gene Therapeuticics LLC | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| JP7200104B2 (ja) * | 2016-08-01 | 2023-01-06 | ヴァイロジン バイオテック カナダ リミテッド | 免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター |
| CN110214148A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白 |
| MA49517A (fr) | 2017-06-30 | 2020-05-06 | Xencor Inc | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène |
| EP3678701A4 (en) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF |
| EP3727146A4 (en) * | 2017-12-19 | 2021-10-06 | Blaze Bioscience, Inc. | CELL PENETRATION PEPTIDE TUMOR AND IMMUNO-ONCOLOGY ADDRESSING AGENT COMPLEXES AND METHODS OF USE |
| PE20201342A1 (es) | 2018-02-28 | 2020-11-25 | Pfizer | Variantes de il-15 y usos de las mismas |
| EP3781599A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| CN112437777A (zh) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白 |
| MX2021004059A (es) | 2018-10-12 | 2021-09-23 | Xencor Inc | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas. |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| MX2021014189A (es) * | 2019-05-20 | 2022-01-06 | Cytune Pharma | Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas. |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| EP4352098A1 (en) | 2021-06-09 | 2024-04-17 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| CA3225985A1 (en) | 2021-07-01 | 2023-01-05 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| WO2023086772A1 (en) | 2021-11-12 | 2023-05-19 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5108910A (en) | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| ES2340745T3 (es) | 1998-12-23 | 2010-06-08 | Pfizer Inc. | Anticuerpos monoclonales humanos contra ctla-4. |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7740845B2 (en) | 2000-10-18 | 2010-06-22 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| EP2330130B1 (en) | 2002-10-17 | 2014-08-27 | Genmab A/S | Human monoclonal antibodies against CD20 |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| JP5744369B2 (ja) | 2004-02-27 | 2015-07-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体 |
| EP1791868B1 (en) | 2004-07-01 | 2011-02-23 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
| WO2006056875A1 (en) | 2004-11-29 | 2006-06-01 | Pharmacia & Upjohn Company Llc | Thiazepine oxazolidinones as antibacterial agents |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| MX2007014474A (es) | 2005-05-17 | 2008-02-07 | Univ Connecticut | Composiciones y metodos para inmunomodulacion en un organismo. |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| TW200837081A (en) | 2006-11-15 | 2008-09-16 | Medarex Inc | Human monoclonal antibodies to BTLA and methods of use |
| EP2133365B1 (en) | 2006-12-27 | 2017-05-17 | Emory University | Compositions and methods for the treatment of infections and tumors |
| EP2121008A4 (en) | 2007-03-22 | 2010-03-31 | Sloan Kettering Inst Cancer | USES OF MONOCLONAL ANTIBODY 8H9 |
| EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| NZ599338A (en) * | 2007-06-27 | 2013-11-29 | Marinepolymer Tech Inc | Complexes of il-15 and il-15ralpha and uses thereof |
| EP2224958A2 (en) | 2007-11-30 | 2010-09-08 | Bristol-Myers Squibb Company | Anti-b7h4 monoclonal antibody-drug conjugate and methods of use |
| US8747847B2 (en) | 2008-02-11 | 2014-06-10 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2009135031A1 (en) | 2008-04-30 | 2009-11-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Substituted il-15 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| KR20110074850A (ko) | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Ｐｄ-１ 길항제 및 그의 사용 방법 |
| US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| CA2736829C (en) | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US20120064096A1 (en) | 2009-03-17 | 2012-03-15 | Universite De La Mediterranee | BTLA Antibodies and Uses Thereof |
| EA201270228A1 (ru) | 2009-07-31 | 2012-09-28 | Медарекс, Инк. | Полноценные человеческие антитела к btla |
| CA2791658C (en) | 2010-03-04 | 2019-10-01 | Macrogenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| CA2791930A1 (en) | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| TR201810298T4 (tr) | 2011-03-31 | 2018-08-27 | Merck Sharp & Dohme | İnsan programlı ölüm reseptörü PD-1'e karşı antikorların stabil formülasyonları ve ilgili tedaviler. |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| AU2013334610B2 (en) * | 2012-10-24 | 2018-09-13 | Novartis Ag | IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes |
| KR102457731B1 (ko) * | 2013-08-08 | 2022-10-21 | 싸이튠 파마 | 병용 약학 조성물 |
-
2014
- 2014-08-08 KR KR1020167005437A patent/KR102457731B1/ko active IP Right Grant
- 2014-08-08 KR KR1020227036248A patent/KR20220148304A/ko not_active IP Right Cessation
- 2014-08-08 JP JP2016532266A patent/JP6794255B2/ja active Active
- 2014-08-08 PL PL14761281T patent/PL3030262T3/pl unknown
- 2014-08-08 CA CA2920539A patent/CA2920539C/en active Active
- 2014-08-08 US US14/910,491 patent/US20160184399A1/en not_active Abandoned
- 2014-08-08 WO PCT/EP2014/002182 patent/WO2015018529A1/en active Application Filing
- 2014-08-08 CN CN201480052637.3A patent/CN105579062A/zh active Pending
- 2014-08-08 EP EP19201668.1A patent/EP3659622A1/en active Pending
- 2014-08-08 SI SI201431420T patent/SI3030262T1/sl unknown
- 2014-08-08 HU HUE14761281A patent/HUE046964T2/hu unknown
- 2014-08-08 LT LTEP14761281.6T patent/LT3030262T/lt unknown
- 2014-08-08 RS RS20191542A patent/RS59756B1/sr unknown
- 2014-08-08 ES ES14761281T patent/ES2760249T3/es active Active
- 2014-08-08 PT PT147612816T patent/PT3030262T/pt unknown
- 2014-08-08 EP EP14761281.6A patent/EP3030262B1/en active Active
- 2014-08-08 DK DK14761281T patent/DK3030262T3/da active
-
2019
- 2019-07-02 JP JP2019123809A patent/JP2019189638A/ja active Pending
- 2019-11-26 CY CY20191101235T patent/CY1122465T1/el unknown
- 2019-12-02 HR HRP20192174TT patent/HRP20192174T1/hr unknown
-
2022
- 2022-02-22 US US17/677,589 patent/US20220168395A1/en active Pending
- 2022-03-15 US US17/695,688 patent/US20220202904A1/en active Pending
- 2022-04-07 JP JP2022063995A patent/JP2022091985A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160040632A (ko) | 2016-04-14 |
| CA2920539A1 (en) | 2015-02-12 |
| JP2019189638A (ja) | 2019-10-31 |
| DK3030262T3 (da) | 2019-12-02 |
| CA2920539C (en) | 2024-01-02 |
| JP6794255B2 (ja) | 2020-12-02 |
| EP3659622A1 (en) | 2020-06-03 |
| EP3030262B1 (en) | 2019-10-09 |
| KR20220148304A (ko) | 2022-11-04 |
| JP2016527286A (ja) | 2016-09-08 |
| CY1122465T1 (el) | 2021-01-27 |
| US20220168395A1 (en) | 2022-06-02 |
| US20160184399A1 (en) | 2016-06-30 |
| US20220202904A1 (en) | 2022-06-30 |
| EP3030262A1 (en) | 2016-06-15 |
| ES2760249T3 (es) | 2020-05-13 |
| KR102457731B1 (ko) | 2022-10-21 |
| SI3030262T1 (sl) | 2020-03-31 |
| RS59756B1 (sr) | 2020-02-28 |
| HUE046964T2 (hu) | 2020-04-28 |
| LT3030262T (lt) | 2020-03-10 |
| PT3030262T (pt) | 2019-12-11 |
| PL3030262T3 (pl) | 2020-07-27 |
| CN105579062A (zh) | 2016-05-11 |
| WO2015018529A1 (en) | 2015-02-12 |
| JP2022091985A (ja) | 2022-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192174T1 (hr) | Kombinirani farmaceutski pripravak | |
| JP2016527286A5 (hr) | ||
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| HRP20231437T1 (hr) | Il-15 i il-15ralpha sushi domena na temelju modulokina | |
| Eggermont et al. | Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies | |
| PH12020550929A1 (en) | Bicyclic peptide ligands specific for epha2 | |
| JP2018503668A5 (hr) | ||
| EA201891074A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии хлл и других видов рака | |
| WO2016022994A3 (en) | High affinity pd-1 agents and methods of use | |
| WO2014089169A4 (en) | Immunotherapy with binding agents | |
| HRP20231570T1 (hr) | Peptid za uporabu u imunoterapiji protiv nesitnostaničnog raka pluća i sitnostaničnog raka pluća | |
| EA201290123A1 (ru) | Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения | |
| HRP20220717T1 (hr) | Modificirani pripravci mrna | |
| RS54233B1 (en) | PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| BR112019011139A2 (pt) | conjugados que compreendem um agonista dual de glp/glucagon, um ligante e ácido hilaurônico | |
| HRP20200085T1 (hr) | Topljivi cd33 za liječenje mijelodisplastičnih sindroma (mds) | |
| HRP20192313T1 (hr) | Novo anti-netrin-1 protutijelo | |
| GB201201314D0 (en) | Composition | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| BR112018004078A2 (pt) | composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo | |
| MY194925A (en) | Composition of fish skin collagen peptides and use thereof as a drug | |
| WO2012140647A3 (en) | Albumin binding probes and drug conjugates thereof | |
| JP2016523558A5 (hr) | ||
| HRP20181021T1 (hr) | Formulacija za bispecifične aktivatore limfocita t (bites) |